COMP <GO>
RPRX vs LLY // EV/EBITDA & P/E VALUATION
Royalty Pharma plc (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: RPRX 6
— LLY 7
▲ EV/EBITDA & P/E VALUATION LEADER: RPRX
LAST: $65.93 (+1.71%) • MKT CAP: $37.91B
valuation
27.8x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 32.36% | -25.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 27.8x | 36.4x | -8.62 | RPRX | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 2.30% | +3.99 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 40.21% | +25.39 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 31.90% | +0.50 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 45.51% | -40.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 9.29 | -6.39 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 66.6 | +2.00 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.51 | +0.43 | RPRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 26.3x | +19.55 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.91B | $1.29T | -$1.26T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | LLY REV | RPRX GROSS % | LLY GROSS % | RPRX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $65.18B | — | 83.0% | $2.38B | $16.81B |
| FY 2024 | $2.26B | $45.04B | — | 81.3% | $2.67B | $8.82B |
| FY 2023 | $2.35B | $34.12B | — | 79.3% | $2.88B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
LLY // BETA 0.51